



Viral Epidemiology Snapshot: January 16-22, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	500	16	3.2%
Flu B	500	1	0.2%
RSV	399	8	2.0%
CoV-2 PUI	1901	590	31.0%
CoV-2 Surveillance	412	37	9.0%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	399	36	9.0%
Coronavirus 229E	399	2	0.5%
Coronavirus HKU1	399	0	0.0%
Coronavirus NL63	399	1	0.3%
Coronavirus OC43	399	24	6.0%
Metapneumovirus	399	52	13.0%
Rhinovirus/Enterovirus	399	59	14.8%
Parainfluenza 1	399	0	0.0%
Parainfluenza 2	399	2	0.5%
Parainfluenza 3	399	4	1.0%
Parainfluenza 4	399	4	1.0%

Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	11
No Subtype	5
Pending subtype	0

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning valley laboratories.

As of 11/14, this report also includes Point-of-Care tests (POCT) for influenza performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

